Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production - PubMed (original) (raw)
. 2005 Apr 1;65(7):2964-71.
doi: 10.1158/0008-5472.CAN-04-4037.
Mauro Signorelli, Marcello Chieppa, Eugenio Erba, Giancarlo Bianchi, Federica Marchesi, Chiara Omero Olimpio, Claudia Bonardi, Annalisa Garbi, Andrea Lissoni, Filippo de Braud, José Jimeno, Maurizio D'Incalci
Affiliations
- PMID: 15805300
- DOI: 10.1158/0008-5472.CAN-04-4037
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production
Paola Allavena et al. Cancer Res. 2005.
Abstract
Yondelis (Trabectedin) is a novel antitumor agent of marine origin extracted from the tunicate Ecteinascidia turbinata. This original compound is active against several human tumors including sarcoma and ovarian and breast adenocarcinoma, as evidenced in phase II clinical trials in advanced multitreated patients. Yondelis is a DNA minor groove binder that blocks cell cycle and interferes with inducible gene transcription in a selective manner. In this study, we investigated the immunomodulatory properties of Yondelis on leukocytes. Human blood monocytes were highly susceptible in vitro to its cytotoxic effect and underwent apoptosis at pharmacologically relevant concentrations (5 nmol/L), whereas lymphocytes were up to 5-fold less sensitive. Macrophages differentiated in vitro with macrophage colony-stimulating factor and tumor-associated macrophages (TAM), isolated from patients with ovarian cancer, were also susceptible. At subcytotoxic concentrations, Yondelis inhibited the in vitro differentiation of monocytes to macrophages. In tumor-treated patients, drug infusion caused a selective decrease of monocyte counts and of ex vivo macrophage differentiation. The in vitro production of two proinflammatory mediators, CCL2 and IL-6, was markedly reduced by Yondelis in monocytes, macrophages, TAM, and freshly isolated ovarian tumor cells. The chemokine CCL2 is the major determinant of monocyte recruitment at tumor sites, whereas IL-6 is a growth factor for ovarian tumors. In view of the protumor activity of TAM and of the strong association between chronic inflammation and cancer progression, the inhibitory effect of Yondelis on macrophage viability, differentiation, and cytokine production is likely to contribute to the antitumor activity of this agent in inflammation-associated human tumors.
Similar articles
- Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells.
Atmaca H, Uzunoglu S. Atmaca H, et al. Eur Cytokine Netw. 2014 Mar 1;25(1):1-7. doi: 10.1684/ecn.2014.0347. Eur Cytokine Netw. 2014. PMID: 24941346 - Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P. Germano G, et al. Cancer Res. 2010 Mar 15;70(6):2235-44. doi: 10.1158/0008-5472.CAN-09-2335. Epub 2010 Mar 9. Cancer Res. 2010. PMID: 20215499 - The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E, Cavallaro E, Damia G, Mantovani R, Di Silvio A, Di Francesco AM, Riccardi R, Cuevas C, Faircloth GT, D'Incalci M. Erba E, et al. Oncol Res. 2004;14(11-12):579-87. doi: 10.3727/0965040042707925. Oncol Res. 2004. PMID: 15666999 - Trabectedin in soft tissue sarcomas.
Brodowicz T. Brodowicz T. Future Oncol. 2014 Jun;10(8 Suppl):s1-5. doi: 10.2217/fon.14.117. Future Oncol. 2014. PMID: 25048043 Review. - Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch, de Vooght MM, López-Lázaro L, Mathôt RA, Schellens JH, Jimeno JM, Beijnen JH. van Kesteren Ch, et al. Anticancer Drugs. 2003 Aug;14(7):487-502. doi: 10.1097/00001813-200308000-00001. Anticancer Drugs. 2003. PMID: 12960733 Review.
Cited by
- Comprehensive analysis of prognostic and immunological role of basement membrane-related genes in soft tissue sarcoma.
Nie GH, Liu CY, Tian Z. Nie GH, et al. Immun Inflamm Dis. 2024 Oct;12(10):e70037. doi: 10.1002/iid3.70037. Immun Inflamm Dis. 2024. PMID: 39392257 Free PMC article. - Radiological evaluation of response in patients with locally advanced/metastatic soft tissue sarcoma treated with trabectedin.
Ceddia S, Onesti CE, Vari S, Torchia A, Cosimati A, Riva F, Maccallini MT, Cerro M, Benvenuti G, Russillo M, Anelli V, Sperduti I, Biagini R, Ferraresi V. Ceddia S, et al. Front Pharmacol. 2024 Aug 20;15:1411707. doi: 10.3389/fphar.2024.1411707. eCollection 2024. Front Pharmacol. 2024. PMID: 39228518 Free PMC article. - A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Jañez NM, Trigo J, Greystoke A, Harvey RD, Olszanski AJ, Opyrchal M, Spira A, Thistlethwaite F, Jiménez B, Sappal JH, Kannan K, Riley J, Li C, Li C, Gregory RC, Miao H, Wang S. Juric D, et al. Cancer Med. 2024 Mar;13(5):10.1002/cam4.6776. doi: 10.1002/cam4.6776. Cancer Med. 2024. PMID: 38501219 Free PMC article. Clinical Trial. - Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment-Progresses in Their Use in Combined Cancer Therapy.
Povo-Retana A, Landauro-Vera R, Alvarez-Lucena C, Cascante M, Boscá L. Povo-Retana A, et al. Molecules. 2024 Jan 9;29(2):331. doi: 10.3390/molecules29020331. Molecules. 2024. PMID: 38257245 Free PMC article. Review. - Metabolic Clues to Bile Acid Patterns and Prolonged Survival in Patients with Metastatic Soft-Tissue Sarcoma Treated with Trabectedin.
Miolo G, Buonadonna A, Scalone S, Lombardi D, Della Puppa L, Steffan A, Corona G. Miolo G, et al. Metabolites. 2023 Sep 26;13(10):1035. doi: 10.3390/metabo13101035. Metabolites. 2023. PMID: 37887360 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources